Literature DB >> 12635090

Molecular and cellular biology of small cell lung cancer.

Martin Sattler1, Ravi Salgia.   

Abstract

For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that in combination render it a malignant neoplasm. Small cell lung cancer (SCLC) is a neoplasm associated with several molecular and cellular abnormalities. SCLC is associated with early and frequent metastasis as well as a poor ultimate response to chemotherapy. New and novel therapies based on understanding the mechanisms of transformation are needed. SCLC is associated with multiple chromosomal abnormalities, the most common of which is chromosome 3p deletion, as well as with abnormal oncogenes and tumor-suppressor genes. Along with the genetic alterations, SCLC has been shown to overexpress various cell surface receptors, including receptor tyrosine kinases (RTKs), G-protein-coupled receptors, integrins, and others. Some downstream molecules are also activated, such as phosphatidylinositol 3'-kinase, and would serve as good candidates for therapeutic strategies. Copyright 2003, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12635090     DOI: 10.1053/sonc.2003.50019

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.

Authors:  Ho-Cheol Kim; Joon Seon Song; Jae Cheol Lee; Dae Ho Lee; Sang-We Kim; Jung-Shin Lee; Woo Sung Kim; Jin Kyung Rho; Sun Ye Kim; Chang-Min Choi
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  Novel combination of 2-methoxyestradiol and cyclophosphamide enhances the antineoplastic and pro-apoptotic effects on S-180 ascitic tumour cells.

Authors:  Srabantika Mallick; Atish Barua; Goutam Paul; Samarendra Nath Banerjee
Journal:  J Cell Commun Signal       Date:  2017-08-10       Impact factor: 5.782

3.  Novel therapeutic approaches for small cell lung cancer: the future has arrived.

Authors:  Maria Catherine Pietanza; Charles M Rudin
Journal:  Curr Probl Cancer       Date:  2012-04-10       Impact factor: 3.187

4.  The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells.

Authors:  S Kalari; M Jung; K H Kernstine; T Takahashi; G P Pfeifer
Journal:  Oncogene       Date:  2012-08-20       Impact factor: 9.867

5.  Valproic acid induces Notch1 signaling in small cell lung cancer cells.

Authors:  Christopher S Platta; David Yü Greenblatt; Muthusamy Kunnimalaiyaan; Herbert Chen
Journal:  J Surg Res       Date:  2008-04-10       Impact factor: 2.192

Review 6.  [The molecular pathogenesis of small cell lung cancer].

Authors:  Sandra P D'Angelo; M Catherine Pietanza
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-11

7.  Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology.

Authors:  Isa Mambetsariev; Tamara Mirzapoiazova; Frances Lennon; Mohit Kumar Jolly; Haiqing Li; Mohd W Nasser; Lalit Vora; Prakash Kulkarni; Surinder K Batra; Ravi Salgia
Journal:  J Clin Med       Date:  2019-07-16       Impact factor: 4.241

8.  Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.

Authors:  Bradley P Coe; Kelsie L Thu; Sarit Aviel-Ronen; Emily A Vucic; Adi F Gazdar; Stephen Lam; Ming-Sound Tsao; Wan L Lam
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

9.  Combinational Therapy Enhances the Effects of Anti-IGF-1R mAb Figitumumab to Target Small Cell Lung Cancer.

Authors:  Hongxin Cao; Wei Dong; Hongchang Shen; Jun Xu; Linhai Zhu; Qi Liu; Jiajun Du
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

Review 10.  Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications.

Authors:  A Quintanal-Villalonga; Luis Paz-Ares; Irene Ferrer; S Molina-Pinelo
Journal:  Dis Markers       Date:  2016-07-26       Impact factor: 3.434

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.